查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1986854

止血和組織密封劑市場規模、佔有率、趨勢和預測：按產品類型、材料類型、應用、最終用戶和地區分類，2026-2034年

Hemostasis and Tissue Sealing Agents Market Size, Share, Trends and Forecast by Product Type, Material Type, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年全球止血和組織密封市場規模為76.8億美元。展望未來，IMARC Group預測，該市場將以5.65%的複合年成長率從2026年成長至2034年，到2034年達到126.1億美元。目前，北美市場主導地位，預計2025年將佔40%的市場。該地區受益於完善的醫療基礎設施、先進的外科技術、止血產品的廣泛應用、有利的報銷政策以及慢性病患病率上升帶來的大量手術，所有這些因素都促進了止血和組織密封市場佔有率的成長。

全球外科手術數量的不斷成長是止血劑和組織封閉劑需求的主要促進因素。在心血管外科、整形外科和一般外科手術中，採用有效的止血管理和組織封閉技術對於改善患者預後、預防術後併發症和出血變得日益重要。糖尿病、癌症和心血管疾病等慢性病的日益普遍也促使需要使用這些專用產品的外科手術需求增加。同時，微創手術的日益普及也影響止血劑和組織封閉劑的需求。此外，老年人口的成長（老年人更容易患慢性病和出現手術併發症）也推動了止血劑和組織封閉劑市場的成長。

美國已成為止血和組織縫合產品的重要市場。美國擁有完善的醫療保健體系，民眾對醫療研發投入龐大，醫生也使用最先進的手術器材。隨著心臟病、糖尿病和癌症發生率的不斷上升，手術變得越來越必要。醫生需要能夠止血並緊密縫合組織。根據CRT集團基金會2022年8月發布的消息，預計2025年至2060年間，美國高血壓患者人數將增加27.2%，從1.278億增至1.625億。 2025年，美國心臟協會（AHA）和美國心臟學會（ACC）將「健康」血壓的目標值設定為130/80 mmHg或更低。此外，由於美國的保險制度補貼了複雜疾病的治療費用、人口老化以及對微創手術的需求不斷成長，美國的止血劑和組織密封劑市場正在迅速成長。

止血劑和組織密封劑市場趨勢

微創手術的需求正在激增。

隨著醫生採用盡可能減少體內切口的手術方法，外科技術正在迅速發展。這改變了醫生止血和修復組織的需求。當醫生使用醫療設備透過極小的切口進行手術時，就需要能夠在狹小空間內使用的專用輔助器具。這些新的手術方法對患者有益，因為它們可以減輕術後疼痛並縮短住院時間。這些手術方法為患者提供了顯著的優勢，例如更短的恢復時間，這促使它們被臨床醫生和患者廣泛接受。隨著對這些技術的支援不斷成長，製造商被迫開發適用於微創手術的先進止血產品。此外，手術器械、高清成像和機器人系統的不斷改進，進一步擴大了微創手術在多個專科領域的應用範圍，從而持續滿足對有效止血解決方案的需求。 2025年，一家都市區醫院引進了一種治療痔瘡的新型微創技術。這使得患者能夠避免與創傷性更大的手術相關的不適，並更快地恢復日常生活。 「拉斐爾療法」是在波蘭開發的，採用射頻消融術在局部麻醉下治療痔瘡，目前在阿波羅光譜醫院進行。

產品配方方面的技術進步

止血和組織密封劑的技術創新顯著提升了產品的功效、安全性和易用性，從而提振了止血和組織密封劑的市場前景。這些新技術包括生物材料的製造、改進的輸送系統以及增強的止血功能，這些功能能夠促進血液凝固和傷口護理。可生物分解和生物相容性製劑會分解，有助於消除人們對其與人體相容性和使用安全性的擔憂。這意味著這些材料會在6到8週內逐漸從體內排放，而無需取出。例如，2025年4月，百特國際在歐洲推出了HemoPatch，這是一種可在室溫下儲存的止血和組織密封劑。這無需冷藏，保存期限長達3年。這些創新將提高手術效率，最大限度地減少產品浪費，並改善開放式手術和微創手術的整體止血效果。

全球慢性病盛行率不斷上升

心血管疾病、癌症和糖尿病等慢性疾病的日益流行是止血劑和組織封閉劑需求的主要促進因素，從而推動了止血劑和組織封閉劑市場的發展。由於慢性疾病的診斷、治療或管理通常需要手術干預，因此對高效止血劑和組織封閉劑的需求始終存在。糖尿病足潰瘍、壓瘡和靜脈潰瘍等慢性傷口是常見的併發症，通常需要手術清創、傷口縫合或處理，因此這些藥物對於確保止血和促進治療至關重要。此外，慢性病患者通常伴隨其他疾病，這會增加手術過程中出血併發症的風險。例如，根據慢性病夥伴關係（PFCD）發布的最新國家和州級統計數據，2024年至2039年間，慢性病可能對美國造成高達47兆美元的損失，導致每年醫療保健支出2.2兆美元，到2039年每年生產力損失約9,000億美元。由生活方式改變、環境因素和人口老化等因素導致的全球疾病負擔日益加重，持續為止血劑創造了龐大的市場。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球止血與組織密封劑市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品類型分類

  • 局部止血劑
  • 黏合劑和組織密封劑

第7章 市場區隔：依材料類型分類

  • 膠原蛋白蛋白
  • 氧化再生纖維素（ORC）
  • 明膠基
  • 多醣
  • 其他

第8章 市場區隔：依應用領域分類

  • 一般外科
  • 微創手術
  • 其他

第9章 市場區隔：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 居家照護設施
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Advanced Medical Solutions Group plc
    • Artivion, Inc
    • B. Braun SE
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • BioCer Entwicklungs-GmbH
    • Ethicon, Inc.（Johnson & Johnson）
    • Medtronic
    • Pfizer Inc.
    • Terumo Aortic
Product Code: SR112026A6397

The global hemostasis and tissue sealing agents market size was valued at USD 7.68 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 12.61 Billion by 2034, exhibiting a CAGR of 5.65% from 2026-2034. North America currently dominates the market, holding a market share of 40% in 2025. The region benefits from well-established healthcare infrastructure, widespread adoption of advanced surgical technologies and hemostatic products, favorable reimbursement policies, and a high volume of surgical procedures driven by the rising prevalence of chronic diseases, all contributing to the hemostasis and tissue sealing agents market share.

The increasing number of surgical procedures being performed across the globe is one of the key drivers that are fueling the demand for hemostasis and tissue sealing agents. Cardiovascular, orthopedic, and general surgeries are increasingly adopting the use of effective hemostatic control and tissue sealing to ensure better patient outcomes and to prevent post-operative complications and blood loss. The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is also contributing to the growing demand for surgical procedures that require the use of these specialized products. At the same time, the increasing adoption of minimally invasive surgical procedures is also influencing the demand for hemostats and tissue sealing agents. Additionally, the expanding geriatric population, which is more susceptible to chronic ailments and surgical complications, is supporting the hemostatic and tissue sealing agents market growth.

The United States has become a place for the market of things that help stop bleeding and seal tissues. The United States has a good healthcare system people are putting a lot of money into medical research and new developments and doctors are using the latest surgical tools. More people are getting sick with things like heart problems, diabetes and cancer so they need to have surgery. The doctors need to be able to stop the bleeding and seal the tissues well. As per information released by the CRT Group Foundation in August 2022, the count of people experiencing hypertension in the United States is expected to rise by 27.2%, reaching 162.5 million from 127.8 million between 2025 and 2060. In 2025, the American Heart Association (AHA) and the American College of Cardiology (ACC) established a specific goal for "healthy" blood pressure, below 130/80 mm Hg. Also, the United States has insurance plans that help pay for complicated illnesses, the population is getting older and more people want to have surgery that is not too invasive so the market for hemostasis and tissue sealing agents in the United States is growing rapidly.

HEMOSTASIS AND TISSUE SEALING AGENTS MARKET TRENDS:

Surging Demand for Minimally Invasive Surgeries

The way doctors do surgery is changing fast because they are using methods that do not cut the body as much. This is changing what doctors need to stop bleeding and fix tissues. When doctors do surgery with machines and tiny cuts they need special helpers that can be used in small spaces. These new ways of doing surgery are beneficial for patients because they hurt less after the surgery they can go home from the hospital sooner. These procedures offer significant patient benefits, including faster recovery times, which have driven their widespread acceptance among both clinicians and patients. The growing preference for these techniques is compelling manufacturers to develop advanced hemostatic products with superior applicability in minimally invasive settings. Moreover, continuous improvements in surgical instrumentation, high-definition imaging, and robotic systems are further expanding the scope of minimally invasive procedures across multiple specialties, sustaining demand for effective hemostatic solutions. In 2025, a novel, minimally invasive technique for addressing haemorrhoids, permitting patients to evade the discomfort of extensive surgery and quickly return to their usual routines, was introduced at a city hospital. The Rafaelo procedure, which involves radiofrequency ablation of hemorrhoids with local anesthesia, was developed in Poland and is being performed at Apollo Spectra.

Technological Advancements in Product Formulations

Technological innovations in hemostasis and tissue sealing agents are significantly enhancing product efficacy, safety, and ease of use, thereby propelling the hemostasis and tissue sealing agents market outlook. These new developments include the production of biomaterials, better delivery systems, and enhanced hemostatic aspects making sure they help blood clot and wounds heal better. Biodegradable and biocompatible agents can be broken down which helps with concerns about how well they work with the body and if they are safe to use. This means the body can slowly get rid of these materials over six to eight weeks without needing to take them out. For instance, in April 2025, Baxter International introduced the Hemopatch sealing hemostat with room-temperature storage in Europe, eliminating the need for refrigeration and offering a three-year shelf life. These innovations enhance surgical efficiency, minimize product wastage, and improve overall hemostatic performance during both open and minimally invasive procedures.

Rising Prevalence of Chronic Diseases Worldwide

The rising incidence of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is a major driver fueling the demand for hemostasis and tissue sealing agents, thus contributing to the hemostasis and tissue sealing agents market forecast. Chronic diseases often require surgical procedures for diagnosis, treatment, or management, thus ensuring a constant demand for efficient hemostatic and tissue sealing agents. Chronic wounds such as diabetic foot, pressure sores, and venous ulcers are frequent complications that often require surgical debridement, closure, or management, where these agents are crucial in ensuring hemostasis and facilitating faster healing. Furthermore, patients with chronic diseases often have comorbid conditions that raise the risk of surgical bleeding complications. For example, new national and state statistics released by the Partnership to Fight Chronic Disease (PFCD) indicate that chronic disease could result in costs of up to $47 trillion for the United States from 2024 to 2039, contributing $2.2 trillion annually in medical expenses and nearly $900 billion annually in lost productivity by 2039. The rising burden of diseases worldwide, driven by lifestyle changes, environmental conditions, and the growing elderly population, continues to create a vast market for hemostatic agents.

HEMOSTASIS AND TISSUE SEALING AGENTS INDUSTRY SEGMENTATION:

Analysis by Product Type:

  • Topical Hemostats
  • Adhesive and Tissue Sealant

Adhesive and tissue sealant holds 54% of the market share. Adhesive and tissue sealant products encompass solutions designed to seal tissues, close wounds, or bond tissues together during surgical procedures. Available in liquid, gel, or film forms, these products are applied directly to the tissue surface, creating a biocompatible barrier that promotes wound healing and prevents leakage or further bleeding. The segment benefits from increasing preference for products that offer faster wound closure, reduced operating times, and lower post-operative infection risks compared to traditional suturing methods. The growing adoption of minimally invasive surgical procedures, where precise tissue sealing through small incisions is essential, is further amplifying demand for advanced sealant solutions. For instance, in November 2023, Ethicon, a part of Johnson and Johnson, gained European approval for its ETHIZIA hemostatic sealing patch, which provides effective results on both sides of the wound and stops bleeding in 30 seconds for 80% of patients.

Analysis by Material Type:

  • Collagen-based
  • Oxidized Regenerated Cellulose (ORC) based
  • Gelatin-based
  • Polysaccharide-based
  • Others

Gelatin-based leads the market with a share of 33%. Gelatin-based hemostats are derived from collagen obtained from animal sources, predominantly bovine or porcine, and possess intrinsic hemostatic properties that are often enhanced through combination with thrombin or other clotting factors. These hemostats are available in various forms, including sponges, powders, and sheets, offering versatility across diverse surgical applications. The segment benefits from the material's proven biocompatibility, cost-effectiveness, and ability to promote both platelet aggregation and wound healing simultaneously. Gelatin-based products are widely used across cardiovascular, orthopedic, and general surgical procedures to control bleeding and facilitate tissue repair. For instance, in 2025, GELITA, a producer of collagen and gelatin, has revealed the introduction of its Endotoxin Controlled Excipients (ECE) range. This product range, including VACCIPRO and MEDELLAPRO, satisfies the rigorous requirements of contemporary biomedical and pharmaceutical uses, such as vaccine stabilization, medical equipment, and 3D bioprinting. The growing demand for reliable and affordable hemostatic solutions in both developed and emerging healthcare systems continues to reinforce the segment's leading position.

Analysis by Application:

  • General Surgery
  • Minimally Invasive Surgery
  • Others

General surgery dominates the market, with a share of 36%. General surgery encompasses a broad spectrum of surgical procedures involving various organs and tissues within the body, including appendectomies, hernia repairs, gallbladder removals, and bowel surgeries. Hemostasis and tissue sealing agents play a crucial role in these procedures by controlling bleeding from incisions, dissected tissues, and damaged vessels, thereby ensuring optimal surgical outcomes and patient recovery. The segment's dominance is underpinned by the sheer volume of general surgical procedures performed annually across healthcare systems worldwide. As surgical complexity increases and patients present with more comorbidities, the need for effective hemostatic control during general surgical interventions continues to expand. For instance, according to the International Journal of Surgery, approximately 310 million major surgeries are carried out annually worldwide, with 40 to 50 million taking place in the United States. The growing emphasis on reducing post-operative complications and improving patient outcomes further supports the segment's leading market position.

Analysis by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

Hospitals represent the leading segment, with a market share of 56%. Hospitals serve as the primary settings for a wide range of medical interventions, including complex surgical procedures that require effective hemostasis and tissue sealing agents. These facilities encompass specialized departments such as operating rooms, emergency departments, and intensive care units where surgeries of varying complexity are performed. The segment's dominance is attributable to the comprehensive resources available within hospital settings, including advanced surgical equipment, trained healthcare personnel, and integrated diagnostic and therapeutic services. Hospitals handle the highest volume of surgical procedures, particularly for chronic disease management, trauma care, and emergency interventions, all of which demand reliable hemostatic products. For instance, according to data published, hospitals held a major percentage share of the hemostasis products market in 2025, reflecting their pivotal role in driving demand. The ongoing expansion of hospital infrastructure globally further reinforces the segment's leading market position in the hemostasis and tissue sealing agents market trends.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 40% of the share, enjoys the leading position in the market. The region's dominance is primarily driven by well-established healthcare infrastructure, high adoption rates of innovative surgical technologies, and the presence of major market players who continuously invest in research and development. North America benefits from a high volume of surgical procedures, particularly for chronic diseases such as cardiovascular disorders, diabetes, and cancer, which create sustained demand for effective hemostatic and tissue sealing products. Favorable reimbursement policies and stringent regulatory standards further support market growth in the region. For instance, the United States minimally invasive surgery market was valued at USD 25.7 Billion in 2024 and is projected to reach USD 36.3 Billion by 2033, growing at a CAGR of 3.73% during 2025-2033, reflecting the strong demand for surgical products including hemostatic agents. Additionally, the well-established network of hospitals and ambulatory surgical centers ensures widespread availability and utilization of these products.

KEY REGIONAL TAKEAWAYS:

UNITED STATES HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

The United States represents the largest national market for hemostasis and tissue sealing agents, driven by the country's extensive healthcare infrastructure, high surgical volumes, and widespread adoption of advanced medical technologies. The rising prevalence of chronic conditions, including cardiovascular diseases, diabetes, and cancer, continues to generate substantial demand for surgical interventions requiring effective hemostatic control. The country's aging population is particularly susceptible to conditions necessitating surgical procedures, further sustaining market demand. Additionally, the United States benefits from strong reimbursement frameworks that support the adoption of advanced hemostatic products across hospitals and ambulatory surgical centers. The growing preference for minimally invasive surgical techniques, including robotic-assisted procedures, is driving demand for hemostats and sealants specifically designed for use through small incisions. A survey commissioned by the Society of Interventional Radiology (SIR) and carried out by The Harris Poll uncovered notable insights regarding the treatment choices available to women diagnosed with uterine fibroids. The survey, involving more than 1,000 women in the USA, revealed that a considerable majority of women diagnosed with uterine fibroids were mainly offered hysterectomy as a treatment option (53%). Conversely, under 20% had knowledge of less invasive options like over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs), uterine fibroid embolization (UFE), oral contraceptives, and endometrial ablation.

EUROPE HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

Europe represents a significant market for hemostasis and tissue sealing agents, supported by a well-developed healthcare system, strong regulatory frameworks, and favorable government-backed reimbursement policies that encourage the adoption of innovative surgical products. The region benefits from high adoption rates of advanced hemostatic solutions across cardiovascular, orthopedic, and general surgical procedures. Key markets including Germany, France, and the United Kingdom drive regional demand through their established hospital networks and ongoing investments in surgical technology. The implementation of the Medical Device Regulation has strengthened product quality standards, promoting the use of clinically validated hemostatic agents. For instance, in April 2025, Baxter International launched the Hemopatch sealing hemostat with room-temperature storage across European markets, eliminating refrigeration requirements and offering enhanced accessibility for surgical teams. Moreover, the growing geriatric population in Europe, coupled with increasing surgical volumes and rising prevalence of chronic diseases, continues to expand the addressable market for hemostatic and tissue sealing products across the region.

ASIA-PACIFIC HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

Asia-Pacific is emerging as the fastest-growing regional market for hemostasis and tissue sealing agents, driven by rapid healthcare infrastructure expansion, rising surgical volumes, and increasing government investments in healthcare across major economies. Countries including China, Japan, India, South Korea, and Australia are witnessing significant improvements in medical facility capabilities, enabling greater adoption of advanced surgical technologies and hemostatic products. The rising prevalence of chronic diseases, expanding medical tourism, and growing awareness of advanced surgical techniques are further catalyzing regional market growth. For instance, in India, nearly 100 out of every 1 lakh people are diagnosed with cancer, underscoring the vast patient population requiring surgical intervention and hemostatic management. Additionally, favorable government policies aimed at improving healthcare access and increasing per capita healthcare expenditure continue to support market expansion across the region.

LATIN AMERICA HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

Latin America presents growing opportunities for hemostasis and tissue sealing agents, supported by improving healthcare infrastructure, rising surgical volumes, and increasing economic development across the region. Brazil, Mexico, and Argentina represent key markets where expanding hospital networks and growing access to advanced surgical technologies are driving demand for hemostatic products. The increasing emphasis on modernizing healthcare systems and improving access to essential surgical services is creating new opportunities for market growth. For instance, the Brazilian government has allocated substantial funding toward expanding public healthcare infrastructure, supporting the growth of surgical services. The growing prevalence of chronic diseases and rising awareness of advanced surgical techniques further support market growth.

MIDDLE EAST AND AFRICA HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

The Middle East and Africa region offers emerging growth potential for hemostasis and tissue sealing agents, driven by ongoing healthcare infrastructure development, increasing government investments in medical facilities, and growing surgical volumes. The region is witnessing rising demand for advanced hemostatic products as healthcare systems expand to address the growing burden of chronic diseases and trauma cases. Moreover, governments are launching public robotic surgery facility, reflecting the broader trend of expanding advanced surgical capabilities across emerging markets. Improving healthcare access and increasing awareness of modern surgical techniques continue to support market development.

COMPETITIVE LANDSCAPE:

The hemostasis and tissue sealing agents market features a moderately consolidated competitive landscape, with several established multinational corporations holding significant market positions through extensive product portfolios, robust distribution networks, and continuous investments in research and development. Key players are actively pursuing strategies including product innovation, strategic acquisitions, geographic expansion, and collaborative partnerships to strengthen their competitive positioning. The market has witnessed notable merger and acquisition activity, with companies seeking to broaden their product offerings and enhance technological capabilities in hemostatic solutions. Additionally, companies are increasingly focusing on developing next-generation hemostatic agents with improved biocompatibility, faster clotting mechanisms, and enhanced storage stability to address evolving surgical requirements across diverse clinical settings worldwide.

The report provides a comprehensive analysis of the competitive landscape in the hemostasis and tissue sealing agents market with detailed profiles of all major companies, including:

  • Advanced Medical Solutions Group plc
  • Artivion, Inc
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BioCer Entwicklungs-GmbH
  • Ethicon, Inc. (Johnson & Johnson)
  • Medtronic
  • Pfizer Inc.
  • Terumo Aortic

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the hemostasis and tissue sealing agents market?

2. What is the future outlook of the hemostasis and tissue sealing agents market?

3. What are the key factors driving the hemostasis and tissue sealing agents market?

4. Which region accounts for the largest hemostasis and tissue sealing agents market share?

5. Which are the leading companies in the global hemostasis and tissue sealing agents market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemostasis and Tissue Sealing Agents Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Topical Hemostats
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Adhesive and Tissue Sealant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Material Type

  • 7.1 Collagen-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxidized Regenerated Cellulose (ORC) based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Gelatin-based
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Polysaccharide-based
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 General Surgery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Minimally Invasive Surgery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Home Care Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Advanced Medical Solutions Group plc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Artivion, Inc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 B. Braun SE
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Baxter International Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Becton, Dickinson and Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 BioCer Entwicklungs-GmbH
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Ethicon, Inc. (Johnson & Johnson)
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Medtronic
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Terumo Aortic
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemostasis and Tissue Sealing Agents Market: Major Drivers and Challenges
  • Figure 2: Global: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Material Type (in %), 2025
  • Figure 6: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Hemostasis and Tissue Sealing Agents (Topical Hemostats) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Hemostasis and Tissue Sealing Agents (Topical Hemostats) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Hemostasis and Tissue Sealing Agents (Adhesive and Tissue Sealant) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Hemostasis and Tissue Sealing Agents (Adhesive and Tissue Sealant) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Hemostasis and Tissue Sealing Agents (Collagen-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Hemostasis and Tissue Sealing Agents (Collagen-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Hemostasis and Tissue Sealing Agents (Oxidized Regenerated Cellulose (ORC) based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Hemostasis and Tissue Sealing Agents (Oxidized Regenerated Cellulose (ORC) based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Hemostasis and Tissue Sealing Agents (Gelatin-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Hemostasis and Tissue Sealing Agents (Gelatin-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Hemostasis and Tissue Sealing Agents (Polysaccharide-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Hemostasis and Tissue Sealing Agents (Polysaccharide-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Hemostasis and Tissue Sealing Agents (Other Material Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Hemostasis and Tissue Sealing Agents (Other Material Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Hemostasis and Tissue Sealing Agents (General Surgery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Hemostasis and Tissue Sealing Agents (General Surgery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Hemostasis and Tissue Sealing Agents (Minimally Invasive Surgery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Hemostasis and Tissue Sealing Agents (Minimally Invasive Surgery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Hemostasis and Tissue Sealing Agents (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Hemostasis and Tissue Sealing Agents (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Hemostasis and Tissue Sealing Agents (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Hemostasis and Tissue Sealing Agents (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Hemostasis and Tissue Sealing Agents (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Hemostasis and Tissue Sealing Agents (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Hemostasis and Tissue Sealing Agents (Home Care Settings) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Hemostasis and Tissue Sealing Agents (Home Care Settings) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Hemostasis and Tissue Sealing Agents (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Hemostasis and Tissue Sealing Agents (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Hemostasis and Tissue Sealing Agents Industry: SWOT Analysis
  • Figure 87: Global: Hemostasis and Tissue Sealing Agents Industry: Value Chain Analysis
  • Figure 88: Global: Hemostasis and Tissue Sealing Agents Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemostasis and Tissue Sealing Agents Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Material Type (in Million USD), 2026-2034
  • Table 4: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Hemostasis and Tissue Sealing Agents Market: Competitive Structure
  • Table 8: Global: Hemostasis and Tissue Sealing Agents Market: Key Players